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Cyclooxygenase-2 (COX-2) is the inducible form of the
enzyme involved in the first two steps of the prostaglandins
and thromboxane synthesis. Up-regulation of COX-2 is
demonstrated in tumors where it can modulate tumoral
progression, metastasis, multidrug resistance and angio-
genesis. Selective COX-2 inhibitors are seen with growing
interest in the tumors treatment. This present study reviews
the COX-2 expression in 32 primary oligodendrogliomas
(24 WHO II; eight WHO III) and two glioblastomas with
prominent oligodendroglial features (WHO IV). Immuno-
histochemical results were compared with survival in order
to verify the COX-2 prognostic significance. COX-2
positivity was found in 44% tumors. Median survival of the
patients with a COX-2 positive lesion was 37 months;
median survival of the patients with a COX-2 negative
lesion was 93 months (P = 0.010). Twenty-nine percent
WHO grade II tumors, 87% WHO grade III, 50% WHO
grade IV resulted COX-2 positive (P = 0.016). In patients
affected by WHO grade II oligodendroglioma, median sur-
vival was 24 and 96 months, respectively, in COX-2 positive
and negative lesions (P = 0.012). In conclusion, even if fur-
ther studies on different, homogeneous and larger series in
vivo are certainly necessary, it is believed that COX-2 could
really have a prognostic value and can be considered as a
possible therapeutic opportunity.
Key words: cyclooxygenase-2, glioma, immunohistochem-
istry, non-steroidal anti-inflammatory drugs, oligodendro-
glioma, prognostic factor.
INTRODUCTION
Cyclooxygenase (COX) is a membrane-bound enzyme
involved in the first two steps of the prostaglandins (PG)
and thromboxane (TX) synthesis from arachidonic acid.
The existence of at least two COX isoforms designated as
COX-1 and COX-2, encoded by separate genes, and cata-
lyzing the same reactions, have been demonstrated. While
COX-1 is constitutively expressed almost ubiquitously in
mammalian tissues, COX-2 is induced by several stimuli
(i.e. proinflammatory signals, hormones, growth factors)
and by certain mutations (i.e. v-src, Ha-ras, HER-2/neu,
Wnt).1–5 However, it has been recently documented that
COX-1 can be induced by VEGF, arachidonic acid, forsko-
lin, dibutyryl-cAMP, and PGE2 and that COX-2 can be
constitutionally expressed in some organs (i.e. brain and
kidney).6–9
Lately, another isoform known as COX-3 has been dem-
onstrated and it is especially abundant in the cerebral cor-
tex and in the heart.10
Numerous studies showed that COX-2 plays a critical
role in the development of neoplasms through various and
not completely clear ways. Increased levels of the COX
enzyme products are present in the neoplastic tissue, where
they can stimulate gene transcription, tumoral growth,
angiogenesis, metastasis and immunosoppression, inhibit
apoptosis, and cause resistance to chemotherapy through
P-glicoprotein-170 over expression.3,11–17 Experimental
data suggest a possible therapeutic use of the COX-
inhibitors. Non-steroidal anti-inflammatory drugs
(NSAID) can block tumor growth through many mecha-
nisms, especially through antiangiogenic and proapoptotic
effects.18,19 Moreover, NSAID can also improve the efficacy
of radiotherapy, chemotherapy and hormonal therapy.18
However, prolonged administration of NSAID can be
problematic because of the toxic effects on the gastrointes-
tinal apparatus and on the kidney related to the inhibition
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of COX-1. For this reason, there is growing interest in
COX-2-selective inhibitors.
Oligodendroglioma is the third most common glial
tumor representing between 5% and 18% of all intracra-
nial gliomas.20 It principally affects the white matter in the
frontal lobe where it is supposed to derive from oligoden-
drocytes or from a precursor cell committed to oligoden-
droglial differentiation.20,21 Although oligodendroglioma
is commonly considered a slow growing chemo-sensible
tumor, it can have a worse outcome locally recurring or
incurring malignant transformation.20
The present study retrospectively reviews the immuno-
histochemical COX-2 expression of 32 consecutive pri-
mary oligodendroglioma and two glioblastomas with
prominent oligodendroglial features in which clinical
data were available. Immunohistochemical results were
compared with survival in order to verify the prognostic
significance.
PATIENTS AND METHODS
Patients
Thirty-four consecutive patients affected by oligodendro-
glioma (32; 94%) or by glioblastoma with prominent oli-
godendroglial features (2; 6%) surgically treated at the
Neurosurgical Service (Careggi Hospital, Florence, Italy)
and at the Department of Neurosurgery (University of
Florence, Florence, Italy) between January 1980 and
December 2001, were studied.
Fifteen (44%) were men and 19 (56%) were women.
Average age at the time of the surgery was 53 years (range
30–78 years).
The majority of the tumors (14 cases, 41%) were local-
ized in the frontal lobe; 1 lesion (3%) took origin at the
medullary conus level (Table 1: patient no. 2).
Resection was considered macroscopically and
radiologically complete in 23 cases (68%) and incomplete
in six (18%). In the remaining five cases (15%) the data on
the surgical completeness were lacking. In all patients
surgery has been performed before any additional
treatment.
Twelve patients (35%) were reoperated on because of a
recurrence. In five, a second recurrence was diagnosed.
Fourteen patients (41%) were treated with nitrosourea-
based chemotherapy (2–31 oral administrations, on aver-
age 10, every 2 months). In 12 cases the chemotherapy
followed the excision of the primary lesion whereas, in
the remaining two cases it followed the surgical treatment
of the recurrence (Table 1: patients no. 13 and 27).
Three patients (9%), one of these after the resection of
the recurrence (Table 1: patient no. 18), underwent
radiotherapy.
The histological diagnosis was executed at the Depart-
ment of Human Pathology and Oncology (University of
Florence, Florence, Italy). Twenty-six oligodendrogliomas
(76%) were pure forms and six (18%) were mixed
oligo-astrocytomas; the remaining two cases (6%) were
glioblastomas with prominent oligodendroglial features.
Twenty-four oligodendrogliomas (71%) were classified as
WHO grade II and eight (24%) as WHO III.20
Median survival (follow-up was available in 29 patients)
was 68 months (range 1–193). At the end of the study, 22
patients had died and seven were alive and free of disease
at 24, 24, 27, 28, 63, 102 and 193 months. Clinical, histo-
pathological and immunohistochemical data are shown in
Table 1.
Immunohistochemical study
Five-mm-thick sections of the most representative speci-
men of each case were mounted on electrostatic slides for
immunohistochemical evaluation. Sections were deparaf-
fined, rehydrated and subjected to antigen retrieval by
automated microwaving (MicroMED T/T Megamilestone
Srl Sorisole Bergamo, Italy) in TEC (Tris-EDTA-Citrate)
buffer ph 7.8 for 36 min. Endogenous peroxidase was
blocked with 3% H2O2 in distilled water. All tumor
specimens were immunostained with primary goat poly-
clonal antibody anti-COX-2 (1:40 dilution; C-20; Santa
Cruz Biotechnology, Santa Cruz, CA, USA) for 2 h at
room temperature. Then, sections were treated with
secondary antibody (1:100 dilution; biotinylated rabbit
antigoat IgG, Dako Cytomation, Glostrup, Denmark) for
1 h and with streptavidin horseradish peroxidase (Labora-
tory Vision, Fremont, CA, USA) for 10 min, developed
with 3,3 diaminobenzidine-hydrogen peroxide (Bio-
Genex, San Ramon, CA, USA) and counterstained with
hematoxylin.
The following procedures were used as negative con-
trols: (i) a non-immune serum in place of the primary anti-
body, and (ii) the primary antibody was omitted. An
ascertained COX-2 positive colon adenocarcinoma was
used as positive control.
COX-2 expression was indicated as ‘+’ when it was
present on the cytoplasm of more than 25% of the cells,
and as ‘–’ when it was focal or absent.
Statistical analysis
Survival was calculated from the date of diagnosis to the
date of death or last follow-up, and was analyzed by the
Kaplan-Meier method. The Log-rank test was used to
assess the strength of association between survival time
and COX-2 expression.
Statistical significance was defined as P < 0.05.
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RESULTS
COX-2 positivity was found in 15 of 34 (44%) tumors (neo-
plastic cells, endothelial cells and cells having the mor-
phological features of neurons and astrocytes). In the
remaining 19 (56%) COX-2 negative cases, endothelial
and occasional cells having the morphological features of
neurons and astrocytes resulted in COX-2 positive
(Table 1; Fig. 1).
Follow-up was available in 29 patients (Table 1).
Median survival of the 13 patients with a COX-2 posi-
tive lesion was 37 months; median survival of the 16
patients with a COX-2 negative lesion was 93 months
(P = 0.010) (Fig. 2).
Seven of 24 (29%) WHO grade II oligodendrogliomas,
seven of eight (87%) WHO grade III, and one of two
(50%) WHO grade IV resulted in COX-2 positive
(P = 0.016) (Fig. 3).
Median survival of 19 patients with a WHO grade II oli-
godendroglioma was 77 months; median survival of the
patients with a WHO grade III was 59 months; median sur-
vival of the patients with a WHO grade IV was 14 months
(P > 0.05; ns).
In the group of 19 patients affected by WHO grade II
oligodendroglioma median survival was 24 and 96 months,
respectively, in COX-2 positive and negative lesions
(P = 0.012) (only one WHO III and one WHO IV lesion
were COX-2 negative) (Fig. 4).
Median survival of 13 patients treated with chemother-
apy was 72 months; in this group median survival was 44
and 89 months, respectively, in COX-2 positive and nega-
tive lesions (P > 0.05; ns).
Fig. 1 Cytoplasmic immunostaining in (A–B) WHO II and (C–D) WHO III oligodendrogliomas; (D) positive endothelial cells;
(E) COX-2 negative oligodendroglioma with entrapped astrocytes showing positive immunoreaction.
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Five of 15 (33%) COX-2 positive and seven of 19 (37%)
COX-2 negative oligodendroglioma relapsed (P > 0.05;
ns).
In the group of patients that were alive at the end of the
study, four (57%), alive at 24, 27, 28, and 102 months, had
COX-2 positive lesions; three (43%), alive at 24, 63, and
193 months, had COX-2 negative lesions.
DISCUSSION
The role of COX-2 has been studied in many pathologies
from arthritis to Alzheimer’s disease to cancer. In the neo-
plastic context, the COX-2 function has been best worked
out in colorectal cancer where robust results indicate an
important role of this enzyme in the tumoral progression:
adenomatous polyps and malignant colonic tumors express
higher level of COX-2 respect to the normal intestinal
mucosa; NSAID significantly reduce the risk of insurgence
of colorectal tumor and the number of the pre-existing
adenoma in adenomatous familial syndrome affected
patients.19,22
Several experimental studies show that the expression
of COX-2 is also detectable in gliomas, and suggest that it
is grade and prognosis related.2,3,14,23–27
The most interesting data regard the possibility of a
therapeutic use of COX-2 inhibitors in the treatment of
gliomas. Already in 1990, it was demonstrated that the
inhibitors of eicosanoid biosynthesis suppress proliferation
and promote differentiation in glioblastoma.28 More
recently, the antitumoral effects of SC-236, NS-398 (selec-
tive COX-2 inhibitors) and of flurbiprofen were proven.2,29
There is a paucity (only two studies) of data about
the expression and the specific role of COX-2 in
oligodendroglioma.23,27
In 2000, Deininger et al. first investigated the expression
of COX-2 in oligodendrogliomas by immunohistochemis-
try.23 They observed a COX-2 immunoreactivity limited at
the astrocytes, neurons and endothelial cells, particularly in
areas of infiltrative tumor growth. The number of COX-2
positive cells was significantly lower in primary oligoden-
drogliomas than in high grade oligodendroglioma
relapsed. The authors supposed a cyclooxygenase accumu-
lation during oligodendroglioma progression in vivo.
In 2003, Castilla et al. studied further, immunohis-
tochemically, COX-2 expression in oligodendrogliomas.27
They noted a cytoplasmic immunoreactivity in tumoral
cells of approximately 18% of cases studied but, contrary
to Deiniger et al., they noted that the reactive astrocytes
were COX-2 negative. Castilla et al. concluded that nega-
Fig. 2 Median survival of 13 patients with COX-2 positive
lesion was 37 months (broken line); median survival of 16
patients with COX-2 negative lesion was 93 months (continu-
ous line) (P = 0.010).
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Fig. 3 Seven of 24 (29%) WHO grade II oligodendroglio-
mas, seven of eight (87%) WHO grade III, and one of two
(50%) WHO grade IV resulted COX-2 positive (light gray)
(P = 0.016).
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Fig. 4 In patients affected by WHO grade II oligodendro-
glioma, median survival was 24 and 96 months, respectively, in
COX-2 positive (broken line) and negative (continuous line)
lesions (P = 0.012).
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tive immunostaining for COX-2 correlated with a higher
survival rate.
In both studies a COX-2 influence on the prognosis was
suggested even if there were discordant results about the
percentage and the prevalent type (astrocytes, neurons and
endothelial cells in the first study, neoplastic cells in the
second study) of cells expressing COX-2, probably related
to the different immunohistochemical methods.
Our present findings documented a frequent (44%)
expression of COX-2 (Fig. 1) in oligodendroglial neo-
plasms (neoplastic cells, entrapped neurons and astrocytes,
and endothelial cells) and gave ulterior support to the
hypothesis that COX-2 can influence the prognosis. In par-
ticular, patients with a COX-2 negative lesion survived
longer than patients with a COX-2 positive lesion when
considering all patients (37 vs 93 months; P = 0.010; Fig. 2)
and also when studying the WHO II oligodendrogliomas
separately (24 vs 96 months; P = 0.012; Fig. 4) (follow-up
occurred for 29 patients). Furthermore, COX-2 resulted in
less expression in low-grade than high-grade lesions (29%
in WHO grade II, 87% in WHO grade III, and 50% in
WHO grade IV lesions; P = 0.016; Fig. 3).
The shown capacity of COX-2 products to stimulate
tumoral growth and progression can explain the poor prog-
nosis of COX-2 positive lesions and the frequent COX-2
expression in high-grade oligodendrogliomas.
In spite of recent data suggesting a possible COX-2
related chemo resistance,13,15,16 we ascertained that the
COX-2 expression does not seem to modify the survival
time in oligodendroglioma affected patients treated with
chemotherapeutic agents (median survival of the patients
treated with chemotherapy was 44 months when COX-2
was positive, and 89 months when COX-2 was negative;
P > 0.05).
In conclusion, although further studies on different,
homogeneous and larger series in vivo are certainly neces-
sary, we believe that COX-2 might really have a prognostic
value and could be considered as a possible therapeutic
opportunity.
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